Chinese pharmaceutical company Livzon Mabpharm Inc. applied for registration of a vaccine against coronavirus infection in Russia. About it informs Kommersant, citing a source close to the Ministry of Health.
According to the publication, the V-01 vaccine produced by Livzon is currently not registered even in China – the second phase of clinical trials is underway there. According to a Kommersant source, the company’s application for clinical trials in Russia is pending.
Representatives of the Ministry of Health declined to comment on Livzon’s application, adding that they did not want to discuss specific drugs. The ministry noted that all information about vaccines approved for clinical trials in the country is posted in the State Register of Medicines – at the moment, only the Chinese vaccine “Convidecia” by CanSino Biologics is listed there.
At the same time, the publication clarifies that more than 5 thousand people participating as volunteers in its trials did not receive official recognition and registration of the fact of their vaccination in the form of a QR code, they were recommended to be vaccinated with one of the Russian vaccines, despite the fact of participation in clinical trials …
On July 6, Health Minister Mikhail Murashko announced that several foreign companies had submitted documents to register their vaccines in Russia. Murashko did not specify what kind of manufacturers he was talking about, adding that all “they are undergoing examination.”
At the moment, four vaccines against coronavirus are officially registered in Russia: Sputnik V and Sputnik Light, developed by the Gamaleya Center, the EpiVacCorona vaccine of the Vector Center, and the Kovivak vaccine, created by the Chumakov Center.